Updated September 10, 2026 — Reviewed against current WHO outbreak guidance and public-health recommendations.
Quick Answer
Bundibugyo virus disease (BVD) is an Ebola disease caused by Bundibugyo virus, a distinct virus in the Orthoebolavirus genus. The 2026 outbreak in the Democratic Republic of the Congo has expanded across multiple provinces and health zones. WHO reports that there is currently no licensed vaccine or specific approved treatment for Bundibugyo virus disease.
What is Bundibugyo virus disease?
Bundibugyo virus disease (BVD) is an Ebola disease caused by Bundibugyo virus, an orthoebolavirus. It is a zoonotic infection, meaning it can pass from animals to humans.
WHO’s latest available situation update says Kayna Health Zone in North Kivu became the latest affected area, bringing the total to 61 affected health zones.
How does Bundibugyo virus spread?
Human infection can occur after close contact with infected wildlife. Once transmission occurs among people, the virus can spread through direct contact with blood, secretions, organs or other body fluids of an infected person, including after death.
Contaminated objects and surfaces can also contribute to transmission. Healthcare workers and caregivers may face particular exposure risks when appropriate infection-prevention measures are not followed. Unsafe burial practices involving direct contact with a deceased person’s body can also facilitate transmission.
Importantly, people infected with Bundibugyo virus disease are generally not infectious before symptoms begin.
What are the symptoms of Bundibugyo virus disease?
Symptoms can initially resemble many other infections, making early clinical diagnosis difficult. The incubation period is 2 to 21 days.
Early symptoms may include:
- Fever
- Extreme tiredness or weakness
- Muscle pain
- Headache
- Sore throat
As illness progresses, patients may develop vomiting, diarrhoea, abdominal pain, rash and problems involving organs such as the kidneys and liver. Bleeding can occur, but it is not present in every patient and may occur later in the illness.
Because malaria and other serious infections can produce similar early symptoms, laboratory testing is needed to confirm Bundibugyo virus disease
How is Bundibugyo virus disease diagnosed?
Diagnosis requires appropriate laboratory testing. WHO lists methods including RT-PCR, antigen detection and antibody-based testing.
Because specimens from people with suspected BVD can pose a serious biological hazard, testing must be performed using appropriate laboratory safety procedures.
Is there a vaccine for Bundibugyo virus?
There is currently no licensed vaccine specifically approved for prevention of Bundibugyo virus disease.
Ervebo is licensed for prevention of Ebola virus disease caused by Ebola virus. WHO says there is currently insufficient evidence to establish that it protects humans against BVD .
WHO reported that more than 2,000 healthcare and frontline workers had received Ervebo in the outbreak response by September 6, 2026.
Is there a treatment for Bundibugyo virus disease?
There is no approved specific therapeutic treatment for BVD at present. However, early intensive supportive care—including rehydration, nutritional support, monitoring and treatment of complications—can improve the chances of survival.
Clinical trials are also evaluating potential treatments for Bundibugyo virus disease. The current outbreak includes the PARTNERS clinical trial, which is investigating treatment options in affected facilities in Ituri.
How serious is the 2026 outbreak?
As of September 7, 2026, WHO reported 6,757 confirmed cases and 3,267 deaths in the DRC, corresponding to a crude case-fatality ratio of 48.3%.
WHO’s risk assessment has classified the risk as very high within the DRC, high for countries sharing its land borders, and low at the regional and global level. WHO has not advised general restrictions on travel or trade with affected countries.
Key takeaway
BVD is a serious form of Ebola disease caused by Bundibugyo virus. There is currently no licensed vaccine or approved specific treatment for BVD. Early recognition, laboratory confirmation, appropriate isolation, supportive medical care, contact tracing and strong infection-prevention measures remain central to controlling the outbreak.
Medical Sources
- World Health Organization — Ebola disease WHO Ebola disease fact sheet
- World Health Organization — Ebola vaccines WHO Ebola vaccines Q&A
- World Health Organization — Immunization, Vaccines and Biologicals: Ebola disease WHO Ebola vaccine information
- World Health Organization — Disease Outbreak News: Bundibugyo virus disease, DRC WHO Disease Outbreak News
Medical Disclaimer
This article is for general educational and informational purposes only. It is not a substitute for professional medical diagnosis, treatment, or individualized medical advice. If you have persistent, severe, worsening, or concerning symptoms, consult a qualified healthcare professional. Seek urgent medical care for emergency symptoms.
Dr. Shabbir Hussain, BPT
Registered Physiotherapist | Clinical Rehabilitation Specialist
Maharashtra OTPT Council Reg. No.: PR-2021/08/PT/009532
Society of Onco Physiotherapists Reg. No.: SOP/00033/LM
Dr. Shabbir Hussain, BPT, Registered Physiotherapist with over 8 years of experience in physiotherapy, kidney rehabilitation, oncological rehabilitation, and lymphedema management. He specializes in balance disorders, pain management, musculoskeletal rehabilitation, strengthening programs, and VR-based rehabilitation.